Golimumab in patients with active rheumatoid arthritis who have previous experience with tumour necrosis factor inhibitors: results of a long-term extension of the randomised, double-blind, placebo-controlled GO-AFTER study through week 160
| Autor: | Norman Gaylis, Jürgen Wollenhaupt, Yiying Zhou, Elizabeth C. Hsia, Josef S Smolen, Robert Landewé, Jonathan Kay, Mittie K. Doyle, Eric L. Matteson, Frederick T. Murphy |
|---|---|
| Přispěvatelé: | Amsterdam institute for Infection and Immunity, Clinical Immunology and Rheumatology |
| Rok vydání: | 2012 |
| Předmět: |
Male
medicine.medical_specialty Immunology Arthritis Placebo General Biochemistry Genetics and Molecular Biology law.invention Arthritis Rheumatoid Double-Blind Method Rheumatology Randomized controlled trial law Internal medicine medicine Humans Immunology and Allergy Adverse effect Dose-Response Relationship Drug Tumor Necrosis Factor-alpha business.industry Antibodies Monoclonal Middle Aged Clinical and Epidemiological Research medicine.disease Golimumab Surgery Clinical trial Antirheumatic Agents Rheumatoid arthritis Female business medicine.drug |
| Zdroj: | Annals of the Rheumatic Diseases Annals of the rheumatic diseases, 71(10), 1671-1679. BMJ Publishing Group |
| ISSN: | 1468-2060 0003-4967 |
| DOI: | 10.1136/annrheumdis-2011-200956 |
| Popis: | Objective The aim of this study was to assess long-term golimumab therapy in patients with rheumatoid arthritis (RA) who discontinued previous tumour necrosis factor alpha (TNFα) inhibitor(s) for any reason. Methods Results through week 24 of this multicentre, randomised, double-blind, placebo-controlled study of active RA (≥4 tender, ≥4 swollen joints) were previously reported. Patients received placebo (Group 1), 50 mg golimumab (Group 2) or 100 mg golimumab (Group 3) subcutaneous injections every 4 weeks. Patients from Groups 1 and 2 with |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|